Market Research Logo

Global Factor IX Deficiency Treatment Market 2017-2021

Global Factor IX Deficiency Treatment Market 2017-2021

About Factor IX Deficiency Treatment

The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.

Technavio’s analysts forecast the global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global factor IX deficiency treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of factor IX products in the different diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Shire
Market driver
  • Growing pipeline with increased focus to meet unmet demand.
  • For a full, detailed list, view our report
Market challenge
  • Emerging price war in the industry.
  • For a full, detailed list, view our report
Market trend
  • Increase in investments in the production and discovery.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
  • Disease overview
    • Table Process of gene therapy
    • Table Key buying criteria and customer segments of global factor IX deficiency treatment market
    • Table Key customer segments of factor IX deficiency treatment market
  • Pipeline analysis
    • Table Pipeline analysis
    • Table Key clinical trials
  • Market landscape
    • Market overview
      • Table Global factor IX deficiency treatment market snapshot
      • Table Global factor IX deficiency treatment market by revenue 2016-2021 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by disease type
    • Global hemophilia B drugs market
      • Table Hemophilia B drugs market for global factor IX deficiency treatment market 2016-2021 ($ millions)
    • Global hemophilia B inhibitors market
      • Table Hemophilia B inhibitors market for global factor IX deficiency treatment market 2016-2021 ($ millions)
  • Market segmentation by type of therapy
    • Recombinant therapies
      • Table Global factor IX recombinant therapies market 2016-2021 ($ millions)
    • Plasma-derived therapies
      • Table Global factor IX plasma-derived therapies market 2016-2021 ($ millions)
  • Market segmentation by type of disease management
    • Table Segmentation of factor IX drugs market by type of disease management 2016
    • Prophylaxis
    • On-demand therapy
    • Inhibitor therapy
  • Geographical segmentation
    • Factor IX drugs market in Americas
      • Table Factor IX deficiency treatment market in Americas 2016-2021 ($ millions)
    • Factor IX drugs market in EMEA
      • Table Factor IX deficiency treatment market in EMEA 2016-2021 ($ millions)
    • Factor IX drugs market in APAC
      • Table Factor IX deficiency treatment market in APAC 2016-2021($ millions)
  • Market drivers
    • Shifting toward half-life drugs
      • Table Launch of half-life drugs for treatment of factor IX deficiency
    • Special designations promote novel launches
      • Table Special designation to factor IX drugs in 2016
    • Growing pipeline with increased focus to meet unmet demand
      • Table A few late-stage (Phase III) factor IX drugs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Emerging price war in the industry
    • Low penetration rate
    • Lack of complete remission
    • High entry barriers
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increasing focus on gene therapy
    • Increase in investments in the production and discovery
    • Strategic initiatives should lead to consolidation
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure of global factor IX deficiency treatment market 2016
      • Table Competitive analysis of global factor IX deficiency treatment market
      • Table Market share analysis 2016
      • Table Market penetration of factor IX vendors 2016
  • Key vendor analysis
    • Biogen
      • Table Biogen: Key highlights
      • Table Biogen: Strength assessment
      • Table Biogen: Strategy assessment
      • Table Biogen: Opportunity assessment
      • Table Year-over-year (YoY) revenue of ALPROLIX 2014-2016 ($ millions)
    • CSL Behring
      • Table CSL Behring: Key highlights
      • Table CSL Behring: Strength assessment
      • Table CSL Behring: Strategy assessment
      • Table CSL Behring: Opportunity assessment
    • Novo Nordisk
      • Table Novo Nordisk: Key highlights
      • Table Novo Nordisk: Strength assessment
      • Table Novo Nordisk: Strategy assessment
      • Table Novo Nordisk: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Shire
      • Table Shire: Key highlights
      • Table Shire: Strength assessment
      • Table Shire: Strategy assessment
      • Table Shire: Opportunity assessment
      • Table Shire: YoY revenue comparison of RIXUBIS 2014 and 2015 ($ millions)
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report